Ruiz-García M, Gutiérrez-Moctezuma J, Garza-Morales S, de la Peña-Olvera F

Idioma: Español
Referencias bibliográficas: 23
Paginas: 145-152
Archivo PDF: 61.12 Kb.

RESUMEN

El trastorno por déficit de atención con hiperactividad es la entidad más frecuente en la consulta pediátrica neuropsiquiátrica. Numerosos estudios sustentan el origen biológico de esta enfermedad. Es un padecimiento crónico que se caracteriza por una tríada de síntomas consistente en inatención, hiperactividad e impulsividad, que afectan el funcionamiento académico, social y laboral de quien lo padece. El diagnóstico se establece de forma clínica; existe una elevada comorbilidad con otras psicopatologías. El abordaje terapéutico debe contemplar tanto la intervención farmacológica como la estrategia principal, siendo los estimulantes la primera línea de elección. Las intervenciones psicosociales son complementarias.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Morgan A. Attention deficit hyperactivity disorder. Pediatr Clin North Am. 1999; 46: 5.

2. American Academy of Pediatrics. Committee on Quality Improvement. Subcommittee on attention-deficit/hyperactivity disorder. Clinical practice guidelines: Diagnosis and evaluation of the child with attention deficit /hyperactivity disorder. Pediatrics. 2000; 105: 1158-70.

3. American Psychiatric Association. Diagnostic and statistical manual of mental disorder (DSM-IV-TR). Washington: American Psychiatric Association; 2000.

4. Ogdie MN. A genome wide scan for attention-deficit/hyperactivity disorder in an extended simple: suggestive linkage 17p11. Am J Hum Genet. 2003; 72: 1268-79.

5. Shaywitz BA, Kopper JH, Yager RD, Gordon JW. Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature. 1976; 261 (5556): 153-5.

6. Shaywitz BA, Yager RD, Klopper JH. Selective dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science. 1976; 191 (4224): 305-8.

7. Shaywitz BA, Teicher MH, Cohen DJ, Anderson GM, Young JG, Levitt P. Dopaminergic but not noradrenergic mediation of hyperactivity and performance deficits in the developing rat pup. Psychopharm. 1984; 82: 73-7.

8. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper T B, et al. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behaviour. Arch Gen Psych. 1989; 46: 587-99.

9. Fuster JM. Cognitive functions in the frontal lobes. En: The human frontal lobes. New York, N.Y.: The Gillford Press; 1999. p. 187-95.

10. Hynd GW, Semrud-Clikeman M, Lorys AR, Novey ES, Eliopulus D, Lyytinen H. Corpus callosum morphology in attention deficit-hyperactivity disorder: morphometric analysis of MRI. J Learn Dis. 1991; 24: 141-6.

11. Hynd GW, Hern KL, Novey ES, Eliopulus D, Marshall R, Gonzalez JJ, et al. Attention deficit-hyperactivity disorder and asymmetry of the caudate nucleus. J Child Neurol. 1993; 8: 339-47.

12. Castellanos FX, Giedd JN, Eckburg P. Quantitative morphology of the caudate nucleus in attention deficit hyperactivity disorder. Am J Psychiatr. 1994; 151: 1791-6.

13. Lou HC, Henriksen L, Bruhn P, Bornr H, Nielsen JB. Striatal dysfunction in attention deficit and hyperkinetic disorder. Arch Neurol. 1989; 46: 48-57.

14. Lou HC, Henriksen L, Bruhn P. Focal cerebral dysfunction in developmental learning disabilities. Lancet. 1990; 335: 8-11.

15. Zametkin AJ, Nordahl TE, Gross M, King AC. Cerebral glucose metabolism in adults with hyperactivity of childhood onset. N Engl J Med. 1990; 323: 1361-6.

16. Stein MA, Baren M. Welcome progress in the diagnosis and treatment of ADHD in adolescence. Contempt Pediatr. 2003; 20: 83-110.

17. Jensen P. ADHD comorbidity and treatment outcome in MTA. J Am Acad Child Adolesc Psychiatr. 2001; 4: 134-57.

18. Biederman J. Pharmacotherapy for ADHD decreases the risk for substance abuse: findings from a longitudinal follow up of youths with and without ADHD. J Clin Psychiatr. 2003; 64 (Suppl 11): 3-8.

19. Connor D. Correlates of comorbid psychopathology in children with ADHD. J Am Acad Child Adolesc Psychiatry. 2003; 42: 193-8.

20. McClellan J. Evidence based treatments in child and adolescent psychiatry: an inventory. Am Acad Child Adolesc Psychiatr. 2003; 42: 1388-400.

21. Multitreatment Approach Cooperative Group: National Institute of Mental Health Multimodal Treatment Study of ADHD Follow Up: 24 month outcomes of Treatment Strategies for ADHD. Pediatrics. 2004; 113: 754-61.

22. Kelsey DK. Once daily atomoxetine treatment for children with attention deficit hyperactivity disorder, including an assessment of evening and morning behavior: a double blind, placebo-controlled trial. Pediatrics. 2004; 114: 1-8.

23. Kutcher S, Aman M, Brooks S. International Consensus Statement on ADHD and disruptive behavior disorders: Clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004; 14: 11-28.